Tarantino P, Carmagnani PR, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. Ca-Cancer J Clin. 2022;72(2):165–82. https://doi.org/10.3322/caac.21705.

Article  PubMed  Google Scholar 

Wu Q, Qian W, Sun X, et al. Small-molecule inhibitors, immune checkpoint inhibitors, and more: fda-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15(1):143. https://doi.org/10.1186/s13045-022-01362-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Z, Li S, Han S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Tar. 2022;7(1):93. https://doi.org/10.1038/s41392-022-00947-7.

Article  CAS  Google Scholar 

Abuhelwa Z, Alloghbi A, Alqahtani A, et al. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in erbb2-positive advanced solid malignancies: a systematic review. Drugs. 2022;82(9):979–87. https://doi.org/10.1007/s40265-022-01736-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hackshaw MD, Danysh HE, Singh J, et al. Incidence of pneumonitis/interstitial lung disease induced by her2-targeting therapy for her2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183(1):23–39. https://doi.org/10.1007/s10549-020-05754-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated her2-positive breast cancer. New Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510.

Article  CAS  PubMed  Google Scholar 

Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-erbb2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7(12):1873–81. https://doi.org/10.1001/jamaoncol.2021.3595.

Article  PubMed  Google Scholar 

Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. Esmo Open. 2022;7(2): 100404. https://doi.org/10.1016/j.esmoop.2022.100404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Z, Shen G, Li J, et al. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: a systematic review and meta-analysis. Crit Rev Oncol Hemat. 2023;184: 103960. https://doi.org/10.1016/j.critrevonc.2023.103960.

Article  Google Scholar 

Antoniou KM, Margaritopoulos GA, Tomassetti S, et al. Interstitial lung disease. Eur Respir Rev. 2014;23(131):40–54. https://doi.org/10.1183/09059180.00009113.

Article  PubMed  PubMed Central  Google Scholar 

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for her2-positive advanced breast cancer. New Engl J Med. 2012;367(19):1783–91. https://doi.org/10.1056/NEJMoa1209124.

Article  CAS  PubMed  Google Scholar 

Yoon S, Shin SJ, Kim HC, et al. Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure. Eur J Cancer. 2022;174:81–9. https://doi.org/10.1016/j.ejca.2022.07.014.

Article  CAS  PubMed  Google Scholar 

Ma Z, Zhang Y, Zhu M, et al. Interstitial lung disease associated with anti-her2 anti-body drug conjugates: results from clinical trials and the who’s pharmacovigilance database. Expert Rev Clin Phar. 2022;15(11):1351–61. https://doi.org/10.1080/17512433.2022.2121705.

Article  CAS  Google Scholar 

Gastaldon C, Raschi E, Kane JM, et al. Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the fda adverse event reporting system. Psychother Psychosom. 2021;90(1):41–8. https://doi.org/10.1159/000510703.

Article  PubMed  Google Scholar 

Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7–8):343–57. https://doi.org/10.1016/j.drudis.2008.12.012.

Article  CAS  PubMed  Google Scholar 

FDA: Fda adverse event reporting system public dashboard. https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html (2023). Accessed 5 Mar 2023.

Capella D, Pedros C, Vidal X, et al. Case-population studies in pharmacoepidemiology. Drug Saf. 2002;25(1):7–19. https://doi.org/10.2165/00002018-200225010-00002.

Article  PubMed  Google Scholar 

Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. https://doi.org/10.7150/ijms.6048.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22(6):bbab347. https://doi.org/10.1093/bib/bbab347.

Article  PubMed  Google Scholar 

Pace ND, Multani JK. On the reporting of odds ratios and risk ratios. Nutrients. 2018;10(10):1512. https://doi.org/10.3390/nu10101512.

Article  PubMed  PubMed Central  Google Scholar 

van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidem Drug Saf. 2002;11(1):3–10. https://doi.org/10.1002/pds.668.

Article  CAS  Google Scholar 

Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769–86. https://doi.org/10.1016/S0140-6736(22)01052-2.

Article  PubMed  Google Scholar 

Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51(4):260–77. https://doi.org/10.1016/j.resinv.2013.09.001.

Article  PubMed  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68. https://doi.org/10.1200/JCO.2017.77.6385.

Article  CAS  PubMed  Google Scholar 

Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42. https://doi.org/10.1093/annonc/mdx225.

Article  CAS  PubMed  Google Scholar 

Marinescu DC, Raghu G, Remy-Jardin M, et al. Integration and application of clinical practice guidelines for the diagnosis of idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Chest. 2022;162(3):614–29. https://doi.org/10.1016/j.chest.2022.06.013.

Article  CAS  PubMed  Google Scholar 

Yong WP, Teo FS, Teo LL, et al. Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opin Drug Metab Toxicol. 2022;18(12):805–15. https://doi.org/10.1080/17425255.2022.2162383.

Article  PubMed  Google Scholar 

Izbicki G, Segel MJ, Christensen TG, et al. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111–9. https://doi.org/10.1046/j.1365-2613.2002.00220.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002;94(3):847–53. https://doi.org/10.1002/cncr.10263.

Article  PubMed  Google Scholar 

Takeda T, Sasaki T, Fukuda K, et al. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Int J Clin Oncol. 2021;26(3):543–51. https://doi.org/10.1007/s10147-020-01827-2.

Article  CAS  PubMed  Google Scholar 

Michielin O, Udry E, Periard D, et al. Irinotecan-induced interstitial pneumonia. Lancet Oncol. 2004;5(5):322–4. https://doi.org/10.1016/S1470-2045(04)01471-8.

Article  CAS  PubMed  Google Scholar 

Ohmori T, Yamaoka T, Ando K, et al. Molecular and clinical features of EGFR-TKI-associated lung injury. Int J Mol Sci. 2021;22(2):792. https://doi.org/10.3390/ijms22020792.

Article  PubMed  PubMed Central  Google Scholar 

Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112–5. https://doi.org/10.1001/jamaoncol.2017.4526.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Ma Z, Sun X, et al. Interstitial lung disease in patients treated with cyclin-dependent kinase 4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Breast. 2022;62:162–9. https://doi.org/10.1016/j.breast.2022.02.011.

Article  PubMed  PubMed Central  Google Scholar 

Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. New Engl J Med. 2022;386(12):1143–54. https://doi.org/10.1056/NEJMoa2115022.

Article  CAS